Higher Semaglutide Dose Shows Promise for Obesity Treatment

In the long human struggle against metabolic disease, a new chapter is being written: international clinical trials now suggest that a higher dose of semaglutide — already a cornerstone of obesity medicine — can deliver meaningfully greater weight loss without a proportional rise in harm. Published in The Lancet Diabetes & Endocrinology, the findings from trials spanning North America and Europe offer a potential path forward for the millions for whom current doses have fallen short. Science rarely delivers clean answers, and researchers are careful to note that long-term questions remain open